<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585442</url>
  </required_header>
  <id_info>
    <org_study_id>22714</org_study_id>
    <secondary_id>10151812</secondary_id>
    <nct_id>NCT00585442</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin D on Renin Expression in Hypertensive Patients</brief_title>
  <official_title>Effects of Calcitriol (1α, 25-[OH]2 Vitamin D3) on Renin Expression in Hypertensive Patients Without Vitamin D Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cardiovascular effects of vitamin D therapy (in humans) have been documented only in
      patients with known vitamin D deficiency or hyperparathyroidism (a surrogate marker of
      inadequate vitamin D activity). It is unknown whether the cardiovascular benefits of vitamin
      D therapy extend beyond these patients to the general hypertensive population. We propose to
      directly measure the effect of vitamin D therapy on plasma renin activity (PRA), plasma renin
      concentration (PRC), renin transcription (in mononuclear leukocytes), and blood pressure in
      hypertensive (but otherwise healthy) patients in a randomized, controlled, experimental
      trial. This will be the first study to assess vitamin D receptor (VDR) biological (PRA, PRC,
      renin mRNA, and polymorphisms) and hypertensive activity in patients without vitamin D
      deficiency. We hypothesize that vitamin D inhibition of renin transcription will produce
      significant reductions in PRA, PRC, renin transcription, inflammatory cytokines, SBP, and
      DBP, with potential variation by VDR genotype. Such a result may prove to be significant in
      the treatment of hypertension, as even modest blood pressure reductions (5 mmHg) are
      associated with a 14% reduction in mortality due to stroke, a 9% reduction in mortality due
      to CHD, and a 7% overall reduction in all-cause mortality.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of quality data
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare plasma renin activity (PRA) and plasma renin concentration (PRC) in hypertensive patients (JNC VII stage I) following 14 days treatment with calcitriol (1α, 25-[OH]2 vitamin D3) or matched placebo.</measure>
    <time_frame>13 MONTHS (MAY 2007-JUNE 2008)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare mononuclear leukocyte renin transcription (mRNA) between calcitriol and matched placebo.</measure>
    <time_frame>13 MONTHS (MAY 2007-JUNE 2008)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcitriol</intervention_name>
    <description>1.0 mcg daily</description>
    <arm_group_label>Calcitriol</arm_group_label>
    <other_name>Rocaltrol</other_name>
    <other_name>1α, 25-[OH]2 Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients age &gt; 55 years.

          2. Female patients must be postmenopausal, as determined by surgical hysterectomy or 12
             month history since last active menstruation

          3. Stage I hypertension (JNC VII Criteria): mean systolic blood pressure (mSBP) 140-159
             mmHg and mean diastolic blood pressure 90 - 99 mmHg (mDBP)2

          4. Provide informed consent

        Exclusion Criteria:

          1. Serum vitamin D &lt;55 pmol/L

          2. Serum calcium &gt;10.5 mg/dL

          3. Serum phosphate (inorganic) &gt;5.5 mg/dL

          4. Serum parathyroid hormone (PTH) &gt;1.3 pmol/L

          5. Vitamin D supplements, calcium supplements, estrogen replacement therapy,
             corticosteroids (inhaled/oral), or hydroxymethyl glutarate CoA reductase inhibitors
             (statins) within 30 days prior to randomization

          6. Stage II hypertension (JNC VII criteria): mSSBP &gt;160 mmHg or mSDBP &gt;100 mmHg

          7. Use of alpha2-agonists, beta-blockers, or more than 2 anti-hypertensive medications at
             screening

          8. Estimated creatinine clearance &lt;30 mL/min by Crockroft-Gault Formula

          9. History of heart failure (HF), acute myocardial infarction (AMI), acute coronary
             syndrome (ACS), transient ischemic attack (TIA), cerebrovascular accident (CVA),
             peripheral vascular disease (PVD), or known clotting disorder

         10. Insulin dependent diabetes mellitus (patients stabilized on oral regimens may be
             enrolled)

         11. History of hypersensitivity reaction to 1α, 25-(OH)2 vitamin D3 (calcitriol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Munger, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>mark munger</investigator_full_name>
    <investigator_title>Professor, Pharmacotherapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

